cagrilintide phase 2 In the REDEFINE 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Anabolic Research Endocrine Research Size:50 Lozenge

cagrilintide phase 2 In the REDEFINE 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Anabolic Research Endocrine Research Size:50 Lozenge

Anabolic Research

Microbial Contamination Without a validated bacteriostatic agent at the correct concentration, microorganisms introduced from the air, the vial stopper, or the syringe will proliferate over the typical 3–4 week refrigerated working window

Endocrine Research

Size:50 Lozenge

A Case series Survival After Paraquat Ingestion: A Case Series When you save one life, you save a family Severe Methemoglobinemia, Unresponsive to Methylene Blue Severe Meliodosis With Multisystemic Involvement: A Case Report A Case Report: Diabetic Ketoacidosis Masking Acute Pancreatitis Recognize Rhabdomyolysis early to prevent Acute Kidney Injury and Acute Renal Failure New Onset Refractory Status Epilepticus (NORSE) Sensitive of EFAST in trauma in correlation with CT scan Sub Arachnoid Haemorrhage, management in Emergency and Neuro Intensive care Uncommon presentation of Takayasu Arteritis as a convulsive syncope All right sided hearts are not Dextrocardia COVID and the Salt Story Acute Lower Limb Ischemia: A Clue to Underlying Aortic Dissection Globe Injury with Orbital Blow Out Fracture The heat-stricken life – Treatment in time only saves lives